开拓药业-B(09939)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

09939 开拓药业-B

休市中 04-10 16:09:18

2.950

+0.270

+10.07%

最高3.050	最低2.710	成交量597.99万
今开2.730	昨收2.680	日振幅12.69%
总市值14.72亿	流通市值14.72亿	总股本4.99亿
成交额1,725万	换手率1.20%	流通股本4.99亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"09939","market":"HK","secType":"STK","nameCN":"开拓药业-B","latestPrice":2.95,"timestamp":1775808558505,"preClose":2.68,"halted":0,"volume":5979852,"delay":0,"changeRate":0.10074626865671642,"floatShares":499000000,"shares":499000000,"eps":-0.5099125501480241,"marketStatus":"休市中","change":0.27,"latestTime":"04-10 16:09:18","open":2.73,"high":3.05,"low":2.71,"amount":17247353,"amplitude":0.126866,"askPrice":2.99,"askSize":15000,"bidPrice":2.95,"bidSize":19000,"shortable":0,"etf":0,"ttmEps":-0.5088741717704923,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1776043800000},"marketStatusCode":7,"adr":0,"listingDate":1590076800000,"exchange":"SEHK","adjPreClose":2.68,"openAndCloseTimeList":[[1775784600000,1775793600000],[1775797200000,1775808000000]],"volumeRatio":1.8792156122783288,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/09939","defaultTab":"news","newsList":[{"id":"2626161538","title":"港股异动 | 开拓药业-B(09939)午后涨近14% 全年收入同比增超五倍 化妆品业务输血核心产品研发","url":"https://stock-news.laohu8.com/highlight/detail?id=2626161538","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626161538?lang=zh_cn&edition=full","pubTime":"2026-04-10 14:19","pubTimestamp":1775801940,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，开拓药业-B(09939)午后涨近14%，截至发稿，涨10.45%，报2.96港元，成交额1412.22万港元。消息面上，开拓药业此前公布年度业绩，实现收益约3270万元，同比增长554%。收益增加主要由于直播电商销售带动高端化妆品品牌KOSHINÉ产品(其主要成分KX826为公司的核心产品之一)的全球销售。集团持续探索不同的方法，进一步推动公司化妆品在全球商业化。公司拟动用化妆品销售业务所得现金流量为公司核心产品KX-826及GT20029以及其他管线产品的开发及商业化提供资金。同时，公司将继续恪守其上市业务的既定方针。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1426990.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["VXUS","BK1161","BK1574","BK4588","BK1515","BK4585","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626159141","title":"电视频道全面清除虚假医药广告；首个iPSC干细胞药获批临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2626159141","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626159141?lang=zh_cn&edition=full","pubTime":"2026-04-10 08:01","pubTimestamp":1775779318,"startTime":"0","endTime":"0","summary":"政策动向广电总局：全国电视频道全面清除虚假宣传医药广告针对广播电视医药广告一度存在的虚假宣传、夸张夸大、用疗效作证明、宣传治愈率有效率等损害人民群众权益问题，国家广播电视总局自2025年8月起在全国范围内开展集中整治，会同省级广电行政部门制定专门工作方案，采取投诉受理、监测排查、研判认定、督促整改等措施，加大处置力度，加强协同治理，确保对违规广告及时发现、准确识别、有效处理。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604103700320740.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604103700320740.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["159938","BK1574","BK1515","BK1161","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626902986","title":"4月9日美诺华涨5.23%，富安达医药创新混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2626902986","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626902986?lang=zh_cn&edition=full","pubTime":"2026-04-09 16:19","pubTimestamp":1775722778,"startTime":"0","endTime":"0","summary":"证券之星消息，4月9日美诺华涨5.23%创60日新高，收盘报45.5元，换手率45.88%，成交量99.2万手，成交额43.82亿元。重仓美诺华的公募基金请见下表：该股最近90天内共有1家机构给出评级，买入评级1家。根据2025基金年报公募基金重仓股数据，重仓该股的公募基金共2家，其中持有数量最多的公募基金为富安达基金的富安达医药创新混合A。富安达医药创新混合A目前规模为0.8亿元，最新净值0.6115，较上一交易日上涨2.05%，近一年上涨21.89%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040900025304.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09939","BK1161","BK1574","BK1515","159938","603538","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626975909","title":"愈尔美医药：未按规范组织生产，召回三批次“医用重组胶原蛋白皮肤创面敷贴”","url":"https://stock-news.laohu8.com/highlight/detail?id=2626975909","media":"蓝鲸财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626975909?lang=zh_cn&edition=full","pubTime":"2026-04-09 15:01","pubTimestamp":1775718071,"startTime":"0","endTime":"0","summary":"蓝鲸新闻4月9日讯，2026年4月7日，广西药品监督管理局发布通告，广西愈尔美医药有限公司报告其委托广东名颜化妆品有限公司生产的“医用重组胶原蛋白皮肤创面敷贴”（桂械注准20242140365）存在未按医疗器械生产质量管理规范组织生产的问题，导致产品存在安全隐患。该公司已对批号为Y0425082001、Y0425082201、Y0425091101的三个批次产品实施三级主动召回。监管部门已要求企业全面排查原因、落实整改措施，并暂停相关产品销售与使用。消费者如已购买上述批次产品，建议立即停止使用并联系企业退换。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1775717364303888961","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["BK1574","09939","159938","BK1161","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626977588","title":"暴降83%！AI“清洗”的不是医药代表，而是无效拜访","url":"https://stock-news.laohu8.com/highlight/detail?id=2626977588","media":"E药经理人","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626977588?lang=zh_cn&edition=full","pubTime":"2026-04-09 10:52","pubTimestamp":1775703120,"startTime":"0","endTime":"0","summary":"一种声音危言耸听，认为AI将彻底替代代表；另一种则固步自封，坚信医药行业依赖人情世故，AI无能为力。AI技术首要冲击的，正是这部分低价值甚至负价值的“动作”。这意味着，未来的“超级医药代表”可能不再是一个单打独斗的拜访高手，而是一位能够娴熟调度多个AI助手的“指挥官”。AI不会让医药代表消失，但它正加速淘汰那些因循守旧、仅凭经验行事、缺乏科学方法的从业者。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-04-09/doc-inhtwhrc8969427.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["AIPO","BK1574","159938","ARTY","BK1161","AGIX","BK1515","09939","CHAT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626971565","title":"港股异动 | 劲方医药-B(02595)早盘涨超5% GFH375获得第二项突破性疗法认定","url":"https://stock-news.laohu8.com/highlight/detail?id=2626971565","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626971565?lang=zh_cn&edition=full","pubTime":"2026-04-09 09:34","pubTimestamp":1775698443,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，劲方医药-B早盘涨超5%，截至发稿，涨4.55%，报37.2港元，成交额553.09万港元。消息面上，劲方医药发布公告，口服KRAS G12D 抑制剂GFH375已被国家药品监督管理局药品审评中心纳入突破性疗法认定名单，拟用于单药治疗至少接受过一种系统性治疗的KRAS G12D突变型转移性胰腺癌患者。GFH375/VS-7375的海外临床研究由劲方合作伙伴Verastem Oncology于去年在美国启动，VS-7375已获得美国FDA快速通道资格认定治疗一线及后线KRAS G12D突变型胰腺导管腺癌。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1426340.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","BK4585","BK1515","09939","159938","VXUS","BK4588","02595","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626697623","title":"北京推出创新医药高质量发展措施；4家集采相关药企进入违规名单","url":"https://stock-news.laohu8.com/highlight/detail?id=2626697623","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626697623?lang=zh_cn&edition=full","pubTime":"2026-04-09 08:30","pubTimestamp":1775694601,"startTime":"0","endTime":"0","summary":"政策动向北京推出32条创新医药高质量发展措施4月7日，北京市医保局等10部门联合发布《北京市支持创新医药高质量发展若干措施（2026年）》，推出32条新举措。其中提出，今年将推动新获批创新药械不少于18个，支持开展国际多中心临床试验不少于120项。若干措施共32条新举措，将坚持北京（京津冀）国际科技创新中心的引领作用，紧跟医药科技发展前沿，布局源头创新。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604093698854245.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604093698854245.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["159938","09939","BK1161","BK1515","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626996975","title":"劲方医药-B(02595)：GFH375获得第二项突破性疗法认定","url":"https://stock-news.laohu8.com/highlight/detail?id=2626996975","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626996975?lang=zh_cn&edition=full","pubTime":"2026-04-09 08:09","pubTimestamp":1775693389,"startTime":"0","endTime":"0","summary":"智通财经APP讯，劲方医药-B 发布公告，口服KRAS G12D 抑制剂GFH375已被国家药品监督管理局药品审评中心纳入突破性疗法认定名单，拟用于单药治疗至少接受过一种系统性治疗的KRAS G12D突变型转移性胰腺癌患者。GFH375/VS-7375 的海外临床研究由劲方合作伙伴Verastem Oncology于2025年在美国启动，VS-7375已获得美国FDA快速通道资格认定治疗一线及后线KRAS G12D突变型胰腺导管腺癌。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1426306.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02595","09939","BK1515","BK1574","159938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625457941","title":"尔康制药：公司践行医药+新能源材料双主业驱动发展战略","url":"https://stock-news.laohu8.com/highlight/detail?id=2625457941","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625457941?lang=zh_cn&edition=full","pubTime":"2026-04-08 20:52","pubTimestamp":1775652772,"startTime":"0","endTime":"0","summary":"证券之星消息，尔康制药04月08日在投资者关系平台上答复投资者关心的问题。公司践行医药+新能源材料双主业驱动发展战略，顺应形势和环境变化，积极转型发展，打造新的利润增长点，努力夯实公司价值创造基础。公司市值管理工作以规范运作为前提、提升经营业绩为核心手段，同时通过多种渠道加强投资者关系管理。重大事项公司将依法依规履行信息披露义务。感谢您对公司的关注。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040800036501.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000941.SH","159938","BK1161","09939","BK0077","BK0239","160640","BK1515","BK0028","399941","BK1574","159875","300267"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625594521","title":"创胜集团-B(06628)拟更改中文股份简称为“创胜集团医药-B”","url":"https://stock-news.laohu8.com/highlight/detail?id=2625594521","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625594521?lang=zh_cn&edition=full","pubTime":"2026-04-08 19:35","pubTimestamp":1775648145,"startTime":"0","endTime":"0","summary":"智通财经APP讯，创胜集团-B(06628)发布公告，公司于香港联合交易所有限公司进行股份买卖的中文股份简称将由“创胜集团-B”更改为“创胜集团医药-B”，自2026年4月13日上午九时正起生效。公司于联交所的英文股份简称、公司名称及股份代号维持不变。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1426139.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159938","BK1161","BK1515","BK1574","06628","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625174219","title":"4月8日欧康医药（920230）龙虎榜数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2625174219","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625174219?lang=zh_cn&edition=full","pubTime":"2026-04-08 17:53","pubTimestamp":1775641984,"startTime":"0","endTime":"0","summary":"证券之星消息，沪深交易所2026年4月8日公布的交易公开信息显示，欧康医药因当日换手率达到20%的前5只股票登上龙虎榜。此次是近5个交易日内第4次上榜。截至2026年4月8日收盘，欧康医药报收于12.98元，下跌5.81%，换手率26.14%，成交量12.35万手，成交额1.62亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040800028160.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159938","BK1574","09939","BK1161","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625391498","title":"4月8日三博脑科涨7.03%，银河医药混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2625391498","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625391498?lang=zh_cn&edition=full","pubTime":"2026-04-08 17:08","pubTimestamp":1775639283,"startTime":"0","endTime":"0","summary":"证券之星消息，4月8日三博脑科涨7.03%，收盘报69.15元，换手率7.31%，成交量11.76万手，成交额7.99亿元。重仓三博脑科的公募基金请见下表：根据2025基金年报公募基金重仓股数据，重仓该股的公募基金共2家，其中持有数量最多的公募基金为银河基金的银河医药混合A。银河医药混合A目前规模为4.29亿元，最新净值0.6113，较上一交易日上涨0.02%，近一年上涨30.84%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040800026300.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","09939","301293","BK1574","BK1515","159938","BK0236"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625844389","title":"广东省药监局：广州合和医药不符合药品GMP要求","url":"https://stock-news.laohu8.com/highlight/detail?id=2625844389","media":"蓝鲸财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625844389?lang=zh_cn&edition=full","pubTime":"2026-04-07 13:22","pubTimestamp":1775539349,"startTime":"0","endTime":"0","summary":"蓝鲸新闻4月7日讯，广东省药品监督管理局于2026年3月31日发布2026年第28号通告，通报近期对省内药品委托生产企业的监督检查情况。本次检查覆盖26家药品上市许可持有人及受托生产企业，涉及委托生产质量管理、工艺合规性、质量协议履行等关键环节。检查发现，25家企业符合要求，广州合和医药有限公司因存在不符合药品GMP的情形被判定为“不符合要求”。监管部门已责令该企业暂停相关风险产品的生产与销售，并采取相应风险控制措施。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1775538677304537936","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["159938","09939","BK1161","BK1515","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625854819","title":"A股三大股指集体上涨，石油化工爆发，消费电子、存储器拉升，医药股调整","url":"https://stock-news.laohu8.com/highlight/detail?id=2625854819","media":"华尔街见闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625854819?lang=zh_cn&edition=full","pubTime":"2026-04-07 10:07","pubTimestamp":1775527643,"startTime":"0","endTime":"0","summary":"早盘存储芯片概念震荡反弹 ，同有科技涨超10%，佰维存储、德明利、伟测科技、普冉股份等跟涨。消费电子概念开盘活跃，折叠屏方向领涨，福蓉科技一字涨停，宜安科技涨超9%，智动力、精研科技、联得装备、安洁科技、大富科技等多股高开。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"789461472c58042ca5eed32a425565d0","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wallstreetcn.com/articles/3769354","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["159732","09939","BK1515","159938","BK1161","BK1574","399300","159982"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625564605","title":"股市必读：欧康医药（920230）登4月3日交易所龙虎榜","url":"https://stock-news.laohu8.com/highlight/detail?id=2625564605","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625564605?lang=zh_cn&edition=full","pubTime":"2026-04-07 02:13","pubTimestamp":1775499190,"startTime":"0","endTime":"0","summary":"截至2026年4月3日收盘，欧康医药报收于14.45元，下跌1.1%，换手率35.11%，成交量16.59万手，成交额2.59亿元。当日关注点来自交易信息汇总：4月3日欧康医药主力资金净流入1204.85万元，占总成交额4.66%。来自交易信息汇总：欧康医药因当日换手率达20%于4月3日登上龙虎榜，系近5个交易日内第2次上榜。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040700000884.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","BK1515","09939","159938","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624591276","title":"4月3日欧康医药（920230）龙虎榜数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2624591276","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624591276?lang=zh_cn&edition=full","pubTime":"2026-04-03 17:42","pubTimestamp":1775209365,"startTime":"0","endTime":"0","summary":"证券之星消息，沪深交易所2026年4月3日公布的交易公开信息显示，欧康医药因当日换手率达到20%的前5只股票登上龙虎榜。此次是近5个交易日内第2次上榜。截至2026年4月3日收盘，欧康医药报收于14.45元，下跌1.1%，换手率35.11%，成交量16.59万手，成交额2.59亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040300034649.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","159938","09939","BK1161","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624183655","title":"4月3日东诚药业跌5.63%，银河医药混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2624183655","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624183655?lang=zh_cn&edition=full","pubTime":"2026-04-03 16:15","pubTimestamp":1775204103,"startTime":"0","endTime":"0","summary":"证券之星消息，4月3日东诚药业跌5.63%，收盘报14.58元，换手率6.08%，成交量45.22万手，成交额6.66亿元。重仓东诚药业的公募基金请见下表：根据2025基金年报公募基金重仓股数据，重仓该股的公募基金共4家，其中持有数量最多的公募基金为银河基金的银河医药混合A。银河医药混合A目前规模为4.29亿元，最新净值0.6285，较上一交易日下跌0.03%，近一年上涨18.38%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040300031235.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159938","BK1515","09939","002675","BK1574","BK0239","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624653385","title":"长春高新：医药创新高投入、长周期、慢回报是行业基本规律","url":"https://stock-news.laohu8.com/highlight/detail?id=2624653385","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624653385?lang=zh_cn&edition=full","pubTime":"2026-04-03 15:27","pubTimestamp":1775201228,"startTime":"0","endTime":"0","summary":"证券之星消息，长春高新04月03日在投资者关系平台上答复投资者关心的问题。正如之前多次回复您提问中提到的费用投入和第二曲线等情况，医药创新高投入、长周期、慢回报是行业基本规律，转型投入与短期营收不匹配并非低效，而是正常阶段特征。公司坚持可控投入、精准培育，希望能够尽快拓展新的增长曲线。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040300024484.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","BK0239","09939","BK1515","BK0075","159938","000661","BK1574","BK0046","BK0057","BK0188","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624329636","title":"特朗普医药新政靴子落地：对部分进口药开征 100% 关税，供应链风险恐加剧","url":"https://stock-news.laohu8.com/highlight/detail?id=2624329636","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624329636?lang=zh_cn&edition=full","pubTime":"2026-04-03 08:30","pubTimestamp":1775176200,"startTime":"0","endTime":"0","summary":"智通财经APP注意到，特朗普政府将对某些进口药品征收高达100%的关税，尽管设有几项重大豁免。声明称，对于与白宫达成协议的主要经济体，其进口产品的关税上限将被设定为15%。该条款允许总统单方面对被视为威胁国家安全的进口产品征收关税。特朗普周四还采取行动，简化并收紧了金属关税。特朗普长期以来一直批评海外药品生产威胁国家安全，并曾提出征收高达200%关税的设想以鼓励国内制造。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1424940.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1515","159938","09939","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624633302","title":"新股消息 | 汇伦医药递表港交所主板","url":"https://stock-news.laohu8.com/highlight/detail?id=2624633302","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624633302?lang=zh_cn&edition=full","pubTime":"2026-04-03 07:20","pubTimestamp":1775172014,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，据港交所4月2日披露，上海汇伦医药股份有限公司向港交所主板提交上市申请书，中信证券为独家保荐人。招股书显示，汇伦医药是一家在药品开发及商业化方面拥有良好过往业绩的制药公司。在此基础上，公司正积极拓展能力，并以针对重大疾病及危重症的创新药物作为战略重点。同时，公司的创新药物管线已取得稳步进展，包括四款I类创新药物及三款II类改良新药目前处于临床开发阶段。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1424923.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1515","BK1161","HEXmain","BK1574","09939","159938"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.kintor.com.cn","stockEarnings":[{"period":"1week","weight":0.1174},{"period":"1month","weight":-0.2416},{"period":"3month","weight":0.3409},{"period":"6month","weight":0.2996},{"period":"1year","weight":1.6818},{"period":"ytd","weight":0.5051}],"compareEarnings":[{"period":"1week","weight":0.0309},{"period":"1month","weight":-0.0002},{"period":"3month","weight":-0.0129},{"period":"6month","weight":-0.0151},{"period":"1year","weight":0.252},{"period":"ytd","weight":0.0103}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"开拓药业有限公司是一家主要从事创新药产品研发的投资控股公司。该公司产品致力于解决未满足临床需求的疾病领域，管线主要涵盖皮科（如脱发、痤疮等）及肿瘤适应症。该公司在皮科领域有两款核心药物KX-826及GT20029。该公司在其他疾病领域包括转移性去势抗性前列腺癌（mCRPC）、肝癌、特发性肺纤维化、恶性血液疾病及多种实体瘤等。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.020286},{"month":2,"riseRate":0.666667,"avgChangeRate":0.174983},{"month":3,"riseRate":0.333333,"avgChangeRate":0.058562},{"month":4,"riseRate":0.666667,"avgChangeRate":0.381722},{"month":5,"riseRate":0.6,"avgChangeRate":0.045244},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.066873},{"month":7,"riseRate":0.666667,"avgChangeRate":0.132768},{"month":8,"riseRate":0.166667,"avgChangeRate":-0.071497},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.129033},{"month":10,"riseRate":0.166667,"avgChangeRate":-0.103242},{"month":11,"riseRate":0.666667,"avgChangeRate":0.073526},{"month":12,"riseRate":0.166667,"avgChangeRate":-0.185801}],"exchange":"SEHK","name":"开拓药业-B","nameEN":"KINTOR PHARMA-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"开拓药业-B(09939)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供开拓药业-B(09939)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"开拓药业-B,09939,开拓药业-B股票,开拓药业-B股票老虎,开拓药业-B股票老虎国际,开拓药业-B行情,开拓药业-B股票行情,开拓药业-B股价,开拓药业-B股市,开拓药业-B股票价格,开拓药业-B股票交易,开拓药业-B股票购买,开拓药业-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"开拓药业-B(09939)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供开拓药业-B(09939)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}